T1	Participants 298 362	patients with diarrhea-dominant irritable bowel syndrome (IBS-D)
T2	Participants 717 797	Thirty-seven patients received S. boulardii and 35 patients received the placebo
T3	Participants 1847 1866	patients with IBS-D
